Publication Name	World Journal of Clinical Oncology
Manuscript ID	116520
Country	Morocco

Category	Oncology
Manuscript Type	Editorial
Article Title	Emergence of human epidermal growth factor receptor 2 as a key biomarker and therapeutic target in advanced urothelial carcinoma
Manuscript Source	Invited Manuscript
All Author List	Nabil Ismaili
Funding Agency and Grant Number
Corresponding Author	Nabil Ismaili, Associate Professor, Chief Physician, Director, MD, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health, Commune Hay Hassani, No. 82403, Casablanca 20000, Morocco. ismailinabil@yahoo.fr
Key Words	Human epidermal growth factor receptor 2; Urothelial carcinoma; Antibody-drug conjugate; Disitamab vedotin; Biomarker
Core Tip	This commentary highlights the critical findings of Huang and He, which establish a strong link between human epidermal growth factor receptor 2 (HER2) overexpression and high-grade upper tract urothelial carcinoma (UC), revealing a distinct biological profile compared to bladder cancer. These results gain immediate clinical relevance with the recent paradigm-shifting data from the phase 3 RC48-C016 trial. The combination of the anti-HER2 antibody-drug conjugate disitamab vedotin and the anti-programmed cell death protein-1 toripalimab has demonstrated superior efficacy over standard chemotherapy in first-line HER2-expressing metastatic UC, nearly doubling progression-free survival and significantly improving overall survival with a better safety profile. Given that nearly half of upper tract UC tumors are HER2-positive, these findings urgently position a substantial patient subset as potential candidates for this novel, biomarker-driven therapy, heralding a new era in UC treatment.
Citation	Ismaili N. Emergence of human epidermal growth factor receptor 2 as a key biomarker and therapeutic target in advanced urothelial carcinoma. World J Clin Oncol 2025; In press

Received	2025-11-13 06:10
Peer-Review Started	2025-11-13 06:10
First Decision by Editorial Office Director	2025-11-21 09:55
Return for Revision	2025-11-21 09:55
Revised	2025-11-21 23:54
Publication Fee Transferred
Second Decision by Editor	2025-12-23 02:34
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2025-12-23 03:32
Articles in Press	2025-12-23 03:32
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com